#ASH18: Cel­gene of­fers up a stel­lar com­plete re­sponse rate for JCAR017. Will any­one no­tice?

It’s get­ting hard­er and hard­er to make a splash with per­son­al­ized CAR-Ts for leukemia and lym­phoma, but Cel­gene is giv­ing it a go to­day at ASH.

Their CAR-T team at Juno — now a sub­sidiary of Cel­gene’s — of­fered up a stel­lar round of ob­jec­tive re­spons­es rates for JCAR017 in their Phase I/II study for a small group of high-risk pa­tients suf­fer­ing from drug re­sis­tant chron­ic lym­pho­cyt­ic leukemia and small lym­pho­cyt­ic lym­phoma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER